Table 1 Summary of all selected cases and our case
Case | Reference (year) | Age | Sex | Site | Diameter (cm) | Gross appearance | Mitoses /10 HPFs | Immunohistochemistry | Procedure | Local recurrence | Metastasis | Outcome | F/U period (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | [9] (2000) | 54 | M | D | 3.2 | Polypoid | > 20 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | OP | N/A | N/A | Death | 37 |
2 | [9] (2000) | 61 | M | A | 4.2 | Sessile | > 20 | α-SMA+, c-kit-, CD34−, S-100− | OP | – | – | Survived | 141 |
3 | [9] (2000) | 75 | M | A | 6.5 | Plaque | > 20 | α-SMA+, c-kit−, CD34−, S-100− | OP | N/A | N/A | Death | 6 |
4 | [9] (2000) | 76 | F | C | 7.8 | Multinodular | > 20 | α-SMA+, c-kit−, CD34−, S-100− | OP | N/A | N/A | Death | 7 |
5 | [9] (2000) | 36 | F | S | 6.5 | Polypoid | > 20 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | OP | – | Lung | Death | 38 |
6 | [9] (2000) | 66 | M | A | N/A | Polypoid | 8 | α-SMA+, c-kit−, CD34−, S-100− | OP | – | Liver | Death | 19 |
7 | [9] (2000) | 41 | M | C | 7.5 | Pedunculated | > 20 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | OP | – | Humerus | Survived | 185 |
8 | [10] (2004) | 65 | M | D | 10 | Polypoid | 2 | α-SMA+, desmin−, c-kit−, CD34−, S-100− | OP | – | + | Death | 28 |
9 | [11] (2004) | 67 | F | T | 5.7 | Polypoid | N/A | α-SMA+, c-kit−, CD34−, S-100− | OP | – | – | Survived | 12 |
10 | [12] (2007) | 77 | F | S | N/A | Intramural | 10–30 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | N/A | + | – | N/A | N/A |
11 | [12] (2007) | 52 | M | S | N/A | Intramural | 10–30 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | N/A | – | Liver | N/A | N/A |
12 | [13] (2011) | 70 | F | S | 3.7 | Intramural | 20 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | Open-Harrtman | – | – | Death | 4 |
13 | [13] (2011) | 56 | M | C | N/A | N/A | N/A | α-SMA+, desmin+, c-kit−, CD34− | Open-RHC | – | Liver | Survived | 68 |
14 | [14] (2012) | 66 | F | S | 3 | Intramural | 20 | α-SMA+, desmin+, c-kit−, CD34−, S-100− | OP | – | Liver | Death | 58 |
15 | [15] (2013) | 94 | F | D | 25 | Type 2 | 30 | α-SMA+, c-kit−, CD34−, S-100− | N/A | – | Liver | Death | 7 |
16 | [15] (2013) | 56 | M | S | 1 | Intramural | 18 | α-SMA+, c-kit−, CD34−, S-100− | N/A | – | LN | Survived | 60 |
17 | [15] (2013) | 78 | F | S | 8.5 | Type 2 | 31 | α-SMA+, c-kit−, CD34−, S-100− | N/A | – | Lung | Death | 16 |
18 | [15] (2013) | 87 | M | T | 11 | Intramural | 102 | α-SMA+, c-kit−, CD34−, S-100− | N/A | – | – | Death | 2 |
19 | [16] (2014) | 66 | F | T | 4 | Polypoid | > 5 | α-SMA+, c-kit−, CD34−, S-100− | Open-RHC | – | – | Survived | 33 |
20 | [17] (2014) | 65 | M | S | N/A | N/A | N/A | α-SMA+, c-kit− | OP | – | – | Survived | 12 |
21 | [18] (2015) | 46 | M | T | 11.8 | Type 2 | 61 | α-SMA+, c-kit−, CD34−, S-100− | Open-RHC | + | – | Survived | 30 |
22 | [19] (2015) | 89 | F | A | 4.5 | N/A | N/A | α-SMA+, c-kit− | Open-RHC | – | Liver | N/A | N/A |
23 | [20] (2015) | 54 | M | A | 13 | Intramural | 10–12 | α-SMA+, desmin+, c-kit−, CD34− | OP | + | – | Survived | > 6 |
24 | [21] (2015) | 59 | M | A | 10 | Exophytic | < 0.5 | α-SMA+, desmin+, c-kit−, CD34−, s-100− | Open-RHC | – | – | Survived | 8 |
25 | [22] (2016) | 82 | M | C | 2.2 | Polypoid | 20 | desmin+, c-kit− | Open-RHC | – | – | Survived | 14 |
26 | [23] (2016) | 51 | F | D | 4 | Type 2 | 10 | α-SMA+, desmin+, c-kit-, CD34-, s-100- | OP | – | – | Survived | 31 |
27 | Our case | 46 | M | S | 4.2 | Polypoid | 39 | α-SMA+, desmin+, c-kit-, CD34-, S-100- | Lap-sigmoidectomy | – | – | Survived | 17 |